AVANIR Announces September 28 Webcast of Investment Community Meeting
SAN DIEGO--(BUSINESS WIRE)--Sept. 24, 2004--AVANIR Pharmaceuticals (AMEX:AVN) invites investors to listen to a live audio webcast of its investment community meeting in New York. The webcast will begin on Tuesday, September 28, 2004 at 4:30 p.m. Eastern Time. The meeting is expected to last approximately one and one half hours.
At this meeting, AVANIR will discuss the positive results of its two pivotal Phase III clinical trials evaluating the safety and effectiveness of Neurodex(TM) in the treatment of pseudobulbar affect (PBA) in patients with neurological conditions such as Lou Gehrig's disease (ALS) and multiple sclerosis (MS).
The meeting will be webcast live through AVANIR's corporate web site at http://www.avanir.com/. Please go to the web site at least ten minutes early to register, download and install any necessary audio software. A replay of the webcast will be available for 90 days.
AVANIR Pharmaceuticals is a drug discovery and development company focused on novel treatments for chronic diseases. The Company's most advanced product candidate, Neurodex(TM), is in Phase III clinical development for pseudobulbar affect, and in Phase II clinical development for neuropathic pain. A potential treatment for allergy and asthma, AVP 13358, is in Phase I clinical development. The Company's first commercialized product, Abreva(R), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com.
AVANIR press releases and presentations, including any forward-looking statements contained therein, should be reviewed in conjunction with the Company's most recent Annual Report on Form 10-K, subsequent quarterly reports on Form 10-Q and other publicly available information regarding the Company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the Company's business and technology. Forward-looking statements often contain such words as "estimate," "anticipate," "intend," "plan" or "expect" and actual results may differ from these forward looking statements. The Company can make no assurances regarding the timing of submission of a new drug application for Neurodex, whether the FDA will accept the Company's new drug application for Neurodex or whether the FDA will ultimately approve Neurodex for commercialization. Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are unpredictable and outside the influence and/or control of the company. Even if Neurodex is approved for commercialization, the Company can make no assurances that it, or any of its marketing partners, will be able to successfully commercialize Neurodex. The Company disclaims any intent or obligation to update these forward-looking statements.
CONTACT: AVANIR Pharmaceuticals: Patrice Saxon, Investor Relations 858-622-5202 email@example.com SOURCE: AVANIR Pharmaceuticals